Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations

IMPORTANCE: DNA repair gene aberrations occur in 20% to 30% of patients with castration-resistant prostate cancer (CRPC), and some of these aberrations have been associated with sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition platinum-based treatments. However, previous trials assessing...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmid, Sabine, Omlin, Aurelius, Higano, Celestia, Sweeney, Christopher, Martinez Chanza, Nieves, Mehra, Niven, Kuppen, Malou C. P., Beltran, Himisha, Condeduca, Vincenza, Vargas Pivato de Almeida, Daniel, Cotait Maluf, Fernando, Oh, William K., Tsao, Che-Kai, Sartor, Oliver, Ledet, Elisa, Di Lorenzo, Giuseppe, Yip, Steven M., Chi, Kim N., Bianchini, Diletta, De Giorgi, Ugo, Hansen, Aaron R., Beer, Tomasz M., Pernelle, Lavaud, Morales-Barrera, Rafael, Tucci, Marcello, Castro, Elena, Karalis, Kostas, Bergman, Andries M., Le, Mo Linh, Zürrer-Härdi, Ursina, Pezaro, Carmel, Suzuki, Hiroyoshi, Zivi, Andrea, Klingbiel, Dirk, Schär, Sämi, Gillessen, Silke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593810/
https://www.ncbi.nlm.nih.gov/pubmed/33112397
http://dx.doi.org/10.1001/jamanetworkopen.2020.21692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593810/
https://www.ncbi.nlm.nih.gov/pubmed/33112397
http://dx.doi.org/10.1001/jamanetworkopen.2020.21692

Ejemplares similares